Results 211 to 220 of about 701,274 (266)

Prolonged Time From Symptoms to Diagnosis Is Associated With an Inferior Progression-Free Survival in Diffuse Large B-Cell Lymphoma. [PDF]

Cancer Med
Tokola S, Marin K, Kuusisto MEL, Kuitunen H, Pollari M, Jyrkkiö S, Suominen M, Vuolukka K, Harmanen M, Sunela K, Rönkä A, Selander T, Aromaa-Häyhä A, Ylhäinen S, Klaavuniemi T, Hakalahti A, Kuittinen O.   +16 more
europepmc   +1 more source

Elevated CircYthdc2 expression is correlated with aggressive features and poor progression-free survival in hepatocellular carcinoma. [PDF]

BMC Gastroenterol
Gong Y, Li X, Wang M.
europepmc   +1 more source

Ki-67 and Platelet-to-Lymphocyte Ratio (PLR) as Predictors of Progression-Free Survival in Metastatic Breast Cancer Receiving CDK4/6 Inhibitors: Clinical Implications. [PDF]

Cancer Manag Res
Gokcek S, Uzun M, Unek IT.
europepmc   +1 more source

Bronchial artery infusion of PD-1 inhibitors plus chemotherapy improves progression-free survival in advanced NSCLC: a prospective cohort study. [PDF]

Sci Rep
Liu B, Zhou J, He W, Zhang R, Cheng X, Xu L, Xie B, Liang Y, Guo S.   +8 more
europepmc   +1 more source

Tissue and peripheral T cell receptor repertoire predicts immunotherapy response and progression-free survival in NSCLC patients. [PDF]

Sci Rep
Pino-González M, Lázaro-Quintela M, Alonso-Álvarez I, Gallardo-Gómez M, Juaneda-Magdalena L, Francisco-Fernández A, Calabuig-Fariñas S, Jantus-Lewintre E, Martínez-Fernández M.   +8 more
europepmc   +1 more source

Development of a lipoprotein(a)-based model for predicting progression-free survival and grade3/4 adverse events in driver gene negative metastatic lung adenocarcinoma patients with PD-L1 TPS <50. [PDF]

Front Immunol
Li S, Cui Y, Yan Y, Li H, Jin Y, Chen Y, Yu J, Feng L.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Concordance index: Surrogacy of progression-free survival for overall survival

Contemporary Clinical Trials, 2021
In oncology clinical trials, the primary endpoint is often time to an event of clinical interest, e.g., time to disease progression or time to death. As a result, progression-free survival (PFS: the time from initiation of treatment till disease progression or death whichever occurs first) and overall survival (OS: the time from initiation of treatment
Yiwei, Fan, Guosheng, Yin
openaire   +2 more sources

The heterogeneity effect of surveillance intervals on progression free survival

Journal of Applied Statistics, 2022
Progression-free survival (PFS) is an increasingly important surrogate endpoint in cancer clinical trials. However, the true time of progression is typically unknown if the evaluation of progression status is only scheduled at given surveillance intervals.
Zihang Zhong, Min Yang, Senmiao Ni, Lixin Cai, Jingwei Wu, Jianling Bai, Hao Yu   +6 more
openaire   +2 more sources

Alternatives to the Kaplan–Meier estimator of progression-free survival

The International Journal of Biostatistics, 2020
Abstract Progression-free survival (PFS), defined as the time from randomization to progression of disease or death, has been indicated as an endpoint to support accelerated approval of certain cancer drugs by the U.S. FDA. The standard Kaplan–Meier (KM) estimator of PFS, however, can result in significantly biased estimates.
Zhang, Jenny J., Sun, Zhuoxin, Yuan, Han, Wang, Molin   +3 more
openaire   +2 more sources